DOCSLIB.ORG

Antidepressants and the Adolescent Brain: Changing the Course of Neurodevelopment?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antidepressants and the Adolescent Brain: Changing the Course of Neurodevelopment? UvA-DARE (Digital Academic Repository) Antidepressants and the adolescent brain: Changing the course of neurodevelopment? Klomp, A. Publication date 2013 Link to publication Citation for published version (APA): Klomp, A. (2013). Antidepressants and the adolescent brain: Changing the course of neurodevelopment?. Boxpress. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:29 Sep 2021 References 233 Appendix ‘t Jong, G.W., van der Linden, P.D., Bakker, E.M., van Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, der Lely, N., Eland, I.A., Stricker, B.H., van den L., Mathews, V.P., Kalnin, A., Lowe, M.J., 2005. Anker, J.N., 2002. Unlicensed and off-label drug Antidepressant effect on connectivity of use in a paediatric ward of a general hospital in the the mood-regulating circuit: an FMRI study. Netherlands. Eur.J.Clin.Pharmacol. 58, 293-297. Neuropsychopharmacology 30, 1334-1344. Abramoff, M.D., Magelhaes P.J., Ram, S.J., 2004. Image Andersen, C.L., Jensen, J.L., Orntoft, T.F., 2004. Processing with ImageJ. 11 ed, pp. 36-42. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance Adriani, W., Laviola, G., 2004. Windows of vulnerability estimation approach to identify genes suited for to psychopathology and therapeutic strategy in the normalization, applied to bladder and colon cancer adolescent rodent model. Behav.Pharmacol. 15, data sets. Cancer Res. 64, 5245-5250. 341-352. Andersen, S.L., 2003. Trajectories of brain development: Adriani, W., Leo, D., Guarino, M., Natoli, A., Di Consiglio, point of vulnerability or window of opportunity? E., De Angelis, G., Traina, E., Testai, E., Perrone- Neurosci.Biobehav.Rev. 27, 3-18. Capano, C., Laviola, G., 2006. Short-term effects of adolescent methylphenidate exposure on brain Andersen, S.L., 2005. Stimulants and the developing striatal gene expression and sexual/endocrine brain. Trends Pharmacol.Sci. 26, 237-243. parameters in male rats. Ann.N.Y.Acad.Sci. 1074, 52- Andersen, S.L., Navalta, C.P., 2004. Altering the course of 73. neurodevelopment: a framework for understanding Aguirre, G.K., Zarahn, E., D’Esposito, M., 1998a. The the enduring effects of psychotropic drugs. Int.J Dev. variability of human, BOLD hemodynamic responses. Neurosci 22, 423-440. NeuroImage 8, 360-369. Andersen, S.L., Navalta, C.P., 2011. Annual Research Aguirre, N., Barrionuevo, M., Lasheras, B., Del Review: New frontiers in developmental Rio, J., 1998b. The role of dopaminergic neuropharmacology: can long-term therapeutic systems in the perinatal sensitivity to 3, effects of drugs be optimized through carefully 4-methylenedioxymethamphetamine-induced timed early intervention? J.Child Psychol.Psychiatry neurotoxicity in rats. J.Pharmacol.Exp.Ther. 286, 52, 476-503. 1159-1165. Andersen, S.L., Teicher, M.H., 2008. Stress, sensitive Alex, K.D., Pehek, E.A., 2007. Pharmacologic periods and maturational events in adolescent mechanisms of serotonergic regulation of dopamine depression. Trends Neurosci. 31, 183-191. neurotransmission. Pharmacol.Ther. 113, 296-320. Anderson, I.M., Del-Ben, C.M., McKie, S., Richardson, Alwan, S., Friedman, J.M., 2009. Safety of selective P., Williams, S.R., Elliott, R., Deakin, J.F., 2007. serotonin reuptake inhibitors in pregnancy. CNS. Citalopram modulation of neuronal responses to Drugs 23, 493-509. aversive face emotions: a functional MRI study. Neuroreport 18, 1351-1355. Amargos-Bosch, M., Artigas, F., Adell, A., 2005. Effects of acute olanzapine after sustained fluoxetine on Anderson, I.M., Juhasz, G., Thomas, E., Downey, D., extracellular monoamine levels in the rat medial McKie, S., Deakin, J.F., Elliott, R., 2011a. The effect prefrontal cortex. Eur.J.Pharmacol. 516, 235-238. of acute citalopram on face emotion processing in remitted depression: a pharmacoMRI study. Eur. American Psychiatric Association, 1994. Diagnostic and Neuropsychopharmacol. 21, 140-148. statistical manual of mental health disorders, 4th ed. American Psychiatric Association, Washington DC. Anderson, I.M., McKie, S., Elliott, R., Williams, S.R., Deakin, J.F., 2008. Assessing human 5-HT function Amico, F., Stauber, J., Koutsouleris, N., Frodl, T., 2011. in vivo with pharmacoMRI. Neuropharmacology 55, Anterior cingulate cortex gray matter abnormalities 1029-1037. in adults with attention deficit hyperactivity disorder: a voxel-based morphometry study. Psychiatry Res. 191, 31-35. 234 References Anderson, I.M., Shippen, C., Juhasz, G., Chase, D., Barbon, A., Popoli, M., La Via, L., Moraschi, S., Vallini, Thomas, E., Downey, D., Toth, Z.G., Lloyd-Williams, I., Tardito, D., Tiraboschi, E., Musazzi, L., Giambelli, K., Elliott, R., Deakin, J.F., 2011b. State-dependent R., Gennarelli, M., Racagni, G., Barlati, S., 2006. alteration in face emotion recognition in depression. Regulation of editing and expression of glutamate Br.J.Psychiatry 198, 302-308. alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol.Psychiatry Andersson, A., Sundman, I., Marcusson, J., 1992. Age 59, 713-720. stability of human brain 5-HT terminals studied with [3H]paroxetine binding. Gerontology 38, 127-132. Bastos, E.F., Marcelino, J.L., Amaral, A.R., Serfaty, C.A., 1999. Fluoxetine-induced plasticity in the rodent Arranz, B., Eriksson, A., Mellerup, E., Plenge, P., visual system. Brain Res. 824, 28-35. Marcusson, J., 1993. Effect of aging in human cortical pre- and postsynaptic serotonin binding sites. Brain Battaglia, G., Yeh, S.Y., O’Hearn, E., Molliver, Res. 620, 163-166. M.E., Kuhar, M.J., De Souza, E.B., 1987. 3,4-Methylenedioxymethamphetamine and Ashburner, J., 2007. A fast diffeomorphic image 3,4-methylenedioxyamphetamine destroy registration algorithm. Neuroimage. 38, 95-113. serotonin terminals in rat brain: quantification Azmitia, E.C., 2001. Modern views on an ancient of neurodegeneration by measurement of [3H] chemical: serotonin effects on cell proliferation, paroxetine-labeled serotonin uptake sites. maturation, and apoptosis. Brain Res.Bull. 56, 413- J.Pharmacol.Exp.Ther. 242, 911-916. 424. Beasley, C.M., Nilsson, M.E., Koke, S.C., Gonzales, Azmitia, E.C., Murphy, R.B., Whitaker-Azmitia, J.S., 2000. Efficacy, adverse events, and treatment P.M., 1990. MDMA (ecstasy) effects on cultured discontinuations in fluoxetine clinical studies of serotonergic neurons: evidence for Ca2(+)- major depression: a meta-analysis of the 20-mg/day dependent toxicity linked to release. Brain Res. 510, dose. J Clin Psychiatry 61, 722-728. 97-103. Beck, A.T., Epstein, N., Brown, G., Steer, R.A., 1988. Aznavour, N., Rbah, L., Riad, M., Reilhac, A., Costes, An inventory for measuring clinical anxiety: N., Descarries, L., Zimmer, L., 2006. A PET imaging psychometric properties. J.Consult Clin.Psychol. 56, study of 5-HT(1A) receptors in cat brain after acute 893-897. and chronic fluoxetine treatment. Neuroimage. 33, Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., 834-842. Erbauch, J., 1961. An inventory for measuring Bachrach, L.K., 2004. Bare-bones fact--children are not depression. Arch.Gen.Psychiatry 4, 561-571. small adults. N.Engl.J.Med. 351, 924-926. Ben Bashat, D., Ben Sira, L., Graif, M., Pianka, P., Hendler, Balu, D.T., 2010. Enhanced sensitivity of the MRL/MpJ T., Cohen, Y., Assaf, Y., 2005. Normal white matter mouse to the neuroplastic and behavioral effects of development from infancy to adulthood: comparing acute and chronic antidepressant treatments. Exp. diffusion tensor and high b value diffusion weighted Clin.Psychopharmacol. 18, 71-77. MR images. J.Magn Reson.Imaging 21, 503-511. Banasr, M., Hery, M., Printemps, R., Daszuta, A., Benes, F.M., Taylor, J.B., Cunningham, M.C., 2000. 2004. Serotonin-induced increases in adult cell Convergence and plasticity of monoaminergic proliferation and neurogenesis are mediated systems in the medial prefrontal cortex during the through different and common 5-HT receptor postnatal period: implications for the development subtypes in the dentate gyrus and the subventricular of psychopathology. Cereb.Cortex 10, 1014-1027. zone. Neuropsychopharmacology 29, 450-460. Benmansour, S., Cecchi, M., Morilak, D.A., Gerhardt, Bao, A.M., Meynen, G., Swaab, D.F., 2008. The stress G.A., Javors, M.A., Gould, G.G., Frazer, A., 1999. system in depression and neurodegeneration: focus Effects of Chronic Antidepressant Treatments on on the human hypothalamus. Brain Res.Rev. 57, 531- Serotonin Transporter Function, Density, and mRNA 553. Level. Journal of Neuroscience 19, 10494-10501. & 235 Appendix Benninghoff, J., van der Ven, A., Schloesser, R.J., Blier, P., de Montigny, C., 1999. Serotonin and drug- Moessner, R., Moller, H.J., Rujescu, D., 2012. The induced therapeutic responses in major depression, complex role of the serotonin transporter in adult obsessive-compulsive and panic disorders. neurogenesis and neuroplasticity. A critical review. Neuropsychopharmacology 21, 91S-98S. World J.Biol.Psychiatry 13, 240-247. Bock, N., Quentin, D.J., Huther, G., Moll, G.H., Berton, O., Hahn, C.G., Thase, M.E., 2012. Are we Banaschewski, T., Rothenberger, A., 2005. Very early getting closer to valid translational models for major treatment with fluoxetine and reboxetine causing depression? Science 338, 75-79. long-lasting change of the serotonin but not the noradrenaline transporter in the frontal cortex of Best, J., Nijhout, H.F., Reed, M., 2010.
Load more

Recommended publications
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • United States Patent [191 [11] Patent Number: 5,017,566 Bodor [45] Date of Patent: ' May 21, 1991
    United States Patent [191 [11] Patent Number: 5,017,566 Bodor [45] Date of Patent: ' May 21, 1991 [54] REDOX SYSTEMS FOR BRAIN-TARGETED FOREIGN PATENT DOCUMENTS DRUG DELIVERY 0197571 10/1986 European Pat. Off. [75] Inventor: Nicholas S. Bodor, Gainesville, Fla. 58-213712 12/1983 Japan . 60-054384 3/1985 Japan . [73] Assignee: University of Florida, Gainesville, 61-070996 4/1986 Japan . Fla. 61-197602 9/1986 Japan . 61-236802 10/1986 Japan . [ ' ] Notice: 7 The portion of the term of this patent 62-“)3795 1/1987 Japan . subsequent to Jan. 8, 2008 has been 62-106901 5/1987 Japan . disclaimed. 62-16470] 7/1987 Japan . 62-281855 12/1987 Japan . [21] Appl. No.: 431,222 63-027440 2/1988 Japan . [22] Filed: Nov. 3, 1989 63-036793 2/1988 Japan . 63-135402 6/1988 Japan . 63-146861 6/1988 Japan . Related US. Application Data 63-218663 9/1988 Japan. [63] Continuation-impart of Ser. No. 139,755, Dec. 30, WO83/03968 11/1983 PCT Int'l Appl. 1987, which is a continuation-in-part of Ser. No. WO85/02767 7/ 1985 PCT lnt'l App], . 174,945, Mar. 29, 1988. WO85/03937 9/1985 PCT Int’l Appl. [30] Foreign Application Priority Data OTHER PUBLICATIONS Dec. 13, 1988 [CA] Canada ........................ .. 585791 Brewster et al, J. Pharm. Sci, vol. 77, No. 11, Nov. Dec. 13, 1988 [IE] Ireland 3717/88 1988, 981-985. Mar. 14, 1989 Ireland ................................. .. 810/89 Brewster et al, in Proceedings of the Fourth International [51] Int. Cl.5 ................... .. A611! 31/735; C0813 37/16 Symposium on Cyclodextrins, Munich, 20th-22nd Apr.
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Special Article: One Resident's Perspective on a Different Style of Psychopharmacological Practice
    Jefferson Journal of Psychiatry Volume 8 Issue 1 Article 4 January 1990 Special Article: One Resident's Perspective on a Different Style of Psychopharmacological Practice Michael Amiel, M.D. North Florida Evaluation / Treatment Center, Gainsville Florida Docteur J.P. Blayac Hospital St. Charles, Montpellier Cedex, France Follow this and additional works at: https://jdc.jefferson.edu/jeffjpsychiatry Part of the Psychiatry Commons Let us know how access to this document benefits ouy Recommended Citation Amiel, M.D., Michael and Blayac, Docteur J.P. (1990) "Special Article: One Resident's Perspective on a Different Style of Psychopharmacological Practice," Jefferson Journal of Psychiatry: Vol. 8 : Iss. 1 , Article 4. DOI: https://doi.org/10.29046/JJP.008.1.001 Available at: https://jdc.jefferson.edu/jeffjpsychiatry/vol8/iss1/4 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Jefferson Journal of Psychiatry by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Special Article: One Resident's Perspective on a Different Style ofPsychopharmacological Practice Michael Arniel, M.D . DocteurJ.P. Blayac This article provides a comparison of psychopharmacological practices in the u.s.and France.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Treatment of Adhd Behandlung Von Adhd Traitement Du Thada
    (19) TZZ _ ¥9B_T (11) EP 2 129 369 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/19 (2006.01) A61K 31/137 (2006.01) 05.06.2013 Bulletin 2013/23 A61P 25/22 (2006.01) A61P 25/26 (2006.01) A61P 25/18 (2006.01) A61P 25/08 (2006.01) (2006.01) (21) Application number: 08700447.9 A61P 25/28 (22) Date of filing: 07.02.2008 (86) International application number: PCT/AU2008/000154 (87) International publication number: WO 2008/095253 (14.08.2008 Gazette 2008/33) (54) TREATMENT OF ADHD BEHANDLUNG VON ADHD TRAITEMENT DU THADA (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR WO-A2-2004/002462 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR • SCHALLER J L ET AL: "Carbamazepine and methylphenidate in ADHD" JOURNAL OF THE (30) Priority: 07.02.2007 US 900043 P AMERICAN ACADEMY OF CHILD AND 30.03.2007 PCT/AU2007/000421 ADOLESCENTPSYCHIATRY, THE ACADEMY, vol. 38, no. 2, 1 February 1999 (1999-02-01), pages (43) Date of publication of application: 112-113, XP009130030 ISSN: 0890-8567 09.12.2009 Bulletin 2009/50 • DAVIDS E. ET AL.: ’A pilot clinical trial of oxcarbazepine in adults with attention-deficit (60) Divisional application: disorder’ PROGRESS IN NEURO- 12174063.3 / 2 505 197 PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY vol. 30, 2006, pages 1033 - 1038, (73) Proprietor: Gosforth Centre (Holdings) Pty Ltd XP005518471 Maroochydore, Queensland 4558 (AU) • SCHREIER H.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]